Glioblastoma’s final stages are defined by a progressive loss of neurological function, and they unfold in a pattern that, while variable from person to person, follows a recognizable trajectory. In the last ten days of life, a hospital-based study found that almost all patients experienced decreasing consciousness, roughly two-thirds had difficulty swallowing and seizures, and nearly nine in ten developed fever. Understanding what these final stages look like, and why they happen, matters for families trying to prepare and for care teams working to keep patients comfortable.
How Glioblastoma Actually Causes Death
Glioblastoma kills in a way that is fundamentally different from most other cancers. While many solid tumors prove fatal through metastasis to vital organs like the liver or lungs, glioblastoma almost never spreads outside the skull. Instead, the tumor grows within a rigid, enclosed space. As it expands, it displaces and compresses the brain tissue around it, steadily raising the pressure inside the skull. Computational models of this process treat brain tissue as a material that partially absorbs and partially transmits the growing tumor’s force, and the resulting pressure distribution depends on the individual patient’s anatomy and how quickly the tumor is expanding.
That rising intracranial pressure is what drives most of the symptoms families observe in the final weeks and days. The brain has limited room to accommodate a growing mass, so as the tumor enlarges, surrounding structures get pushed aside. Critical areas that control consciousness, breathing, and heart rate can be compressed. In the most severe cases, brain tissue herniates, meaning it gets pushed through openings in the skull’s internal structures, which is rapidly fatal.
A retrospective study of patients with high-grade gliomas cataloged the specific causes of death. Beyond the direct effects of the tumor itself, infections accounted for roughly one in eight deaths, seizures for about one in twenty, and intratumoral hemorrhage, cerebral edema, and pulmonary embolism each played smaller roles.1PubMed Central. Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study For patients who ended up in the ICU on mechanical ventilation, in-hospital mortality reached about 60%, driven largely by sepsis and multi-organ failure.2PubMed Central. Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis This means that while the tumor itself is the root cause, the immediate trigger of death is often a cascade of secondary complications: the patient becomes immobile, the immune system weakens, and infections take hold.
Personality and Cognitive Changes Along the Way
One of the most distressing aspects of glioblastoma, and the one families are often least prepared for, is how the tumor changes who a person seems to be. Because the tumor sits in the brain itself, it can alter personality, mood, and behavior in ways that feel profoundly different from the physical decline seen in other cancers. A systematic review found that reported rates of personality and behavioral changes in glioma patients ranged widely, from 8% to 67% depending on the study and the tumor’s location, and reached 100% in a small case series of patients with tumors growing in both hemispheres.3PubMed Central. Prevalence of changes in personality and behavior in adult glioma patients: a systematic review These changes were also linked to significant distress for both patients and their caregivers.
The nature of the personality shift depends on where the tumor is located. Frontal lobe tumors tend to produce apathy, impulsivity, or social disinhibition. Temporal lobe involvement may affect emotional processing and memory. Some patients become uncharacteristically irritable or aggressive; others become withdrawn and flat. Depression and anxiety are common throughout the disease course, and memory loss, fatigue, agitation, and delirium all increase as the tumor progresses. These are not purely emotional responses to having a terminal illness. They are direct neurological consequences of the tumor infiltrating and compressing brain tissue.
For families, the hardest part is often the ambiguity. A patient who says something hurtful or uncharacteristic may not be expressing their true feelings; their frontal lobe may simply be compromised. A patient who stops engaging with loved ones may not have emotionally checked out; their ability to initiate conversation and process language may have been physically disrupted. Knowing this distinction does not make the experience less painful, but it can relieve some of the guilt and confusion caregivers carry.
What the Final Ten Days Look Like
A study that assessed 57 glioblastoma patients who died in a hospital setting tracked their clinical signs during the last ten days of life. The findings paint a stark picture: a decrease in the level of consciousness was present in 95% of patients, fever appeared in 88%, difficulty swallowing in 65%, seizures in 65%, and headache in 33%.4PubMed. The Last 10 Days of Patients With Glioblastoma: Assessment of Clinical Signs and Symptoms as well as Treatment The overall trajectory in those final days is one of progressive disconnection from the surrounding world, punctuated by acute events like seizures or fevers.
Loss of consciousness and swallowing difficulty tend to arise in the last week before death, often within days of each other.5PubMed Central. Symptoms and problems in the end-of-life phase of high-grade glioma patients Swallowing is one of the most consequential losses in practical terms, because it marks the point where oral medications can no longer be given. A patient who has been managing symptoms with pills suddenly needs alternative routes of drug delivery, and families who have been providing food and water face the reality that their loved one can no longer safely eat or drink. This moment often triggers intense distress for caregivers, even when they intellectually understand what is happening.
The decline in consciousness typically follows a recognizable path. Early on, the patient may seem drowsy or confused, responding to conversation but not initiating it. Over days, responsiveness narrows to physical stimuli like touch or sound. Eventually, the patient enters a state where they no longer respond at all, though it remains unclear how much they can still perceive. This uncertainty is one of the hardest parts for families at the bedside.
Headache, present in a third of patients in the final days, is worth noting because it is one of the few symptoms where the patient may still be experiencing suffering even as they become less communicative. If a patient is grimacing, furrowing their brow, or becoming restless when they cannot speak, pain is a reasonable assumption, and treatment should not wait for the patient to verbally confirm it.
Seizures When Oral Medications Fail
Seizures are one of the most frightening symptoms for families to witness, and they are common in the end-of-life phase of glioblastoma. They occur frequently in the final days and present a unique management challenge: the very patients who need anti-seizure medication most are the ones who can no longer swallow it.6PubMed Central. Epilepsy in the end of life phase of brain tumor patients: a systematic review
This is not a hopeless situation. A feasibility study tested non-oral routes for seizure control and found that buccal clonazepam, a medication placed inside the cheek and absorbed through the mucous membrane, kept roughly 60% of patients seizure-free as a preventive treatment. For breakthrough seizures, intranasal midazolam, sprayed into the nose, achieved seizure control in every patient who received it. None of the patients in the study needed to be transferred to a hospital because of uncontrolled seizures.7PubMed Central. Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study These results suggest that seizure management at home or in hospice is genuinely achievable, even in the final days, as long as the right medications are available and caregivers know how to administer them.
Families should discuss seizure contingency plans with the palliative care team well before the patient loses the ability to swallow. Having non-oral seizure medications on hand, with clear instructions for use, can prevent panicked emergency room visits in the final days. It also gives caregivers a sense of agency during a period when everything else feels out of their control.
Fever, Autonomic Storms, and Unexpected Physical Symptoms
The 88% prevalence of fever in the last ten days raises an obvious question: are these patients fighting infections, or is something else going on? The answer is often both. As patients become immobile and their immune defenses weaken, infections like pneumonia and urinary tract infections become common and are a direct cause of death in a meaningful fraction of cases. But fever in glioblastoma can also occur without any infection at all.
A phenomenon called paroxysmal autonomic dysregulation, sometimes described as “autonomic storming,” can cause sudden episodes of high fever, rapid heart rate, fast breathing, elevated blood pressure, dilated pupils, agitation, and abnormal posturing. This happens when the tumor or rising intracranial pressure disrupts the brain’s autonomic control centers, the regions that regulate body temperature, heart rate, and blood pressure without conscious input.8PubMed Central. Paroxysmal autonomic dysregulation with fever that was controlled by propranolol in a brain neoplasm patient These episodes can look alarming, resembling a severe infection or a medical emergency, but they are fundamentally neurological in origin. Medications like propranolol, a beta-blocker, have been used to manage them.
For caregivers, the practical implication is that fever in the final days of glioblastoma does not always mean a new infection that needs aggressive antibiotic treatment. When patients are already in the dying process, treating a central fever caused by autonomic dysregulation is more about comfort than cure. This is a conversation worth having with the medical team in advance, because decisions made in the heat of a fever spike tend to default toward aggressive intervention unless everyone has already agreed on comfort-focused goals.
Steroids and Their Complicated Role
Dexamethasone, a corticosteroid, is one of the most commonly used medications throughout the glioblastoma disease course. It reduces swelling around the tumor, which in turn lowers intracranial pressure and can dramatically improve symptoms like headache, nausea, and neurological deficits. Clinical guidelines recommend a maximum of 16 mg daily for symptomatic patients after surgery, with a tapering schedule as quickly as tolerated. For patients near the end of life who still benefit from it, a low maintenance dose of 0.5 to 1.0 mg daily is suggested.9PubMed Central. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline
Steroids occupy a strange space in end-of-life care. On one hand, they can provide real relief from pressure-related symptoms and buy meaningful quality time. On the other, long-term use causes muscle wasting, weight gain concentrated in the face and trunk, insomnia, mood swings, elevated blood sugar, and immune suppression. The immune suppression is particularly consequential near the end of life, because it increases the risk of the infections that are already one of the leading causes of death in this population.
There is no universally right answer about when to continue or stop steroids. Some families and patients decide that the neurological benefits are worth the side effects for as long as possible. Others reach a point where the steroid side effects are causing more suffering than the swelling they were treating. When steroids are discontinued, symptoms from tumor-related edema can return rapidly, sometimes within a day or two, so this decision is typically made in close conversation with the care team and ideally with guidance from the patient’s previously stated wishes.
When Symptoms Cannot Be Controlled
Despite best efforts, some patients in the final days experience symptoms that resist standard treatment: uncontrolled delirium, severe agitation, refractory seizures, or labored breathing with a “death rattle.” In a cohort of glioblastoma patients receiving home palliative care, palliative sedation with midazolam was necessary in about 11% of cases to achieve adequate comfort.10PubMed. Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients
Palliative sedation involves using medication to lower the patient’s level of consciousness enough that they are no longer experiencing distress from symptoms that cannot otherwise be managed. It is not euthanasia, and the distinction matters both ethically and practically. The intent is to relieve suffering, not to hasten death, and the dose is titrated to the minimum level needed for comfort. In most countries and healthcare systems, palliative sedation for refractory symptoms is an established and accepted part of end-of-life care.
Families sometimes feel guilt or conflict about agreeing to palliative sedation, especially if the patient has not previously discussed it. The worry is that sedation means “giving up” or that it will shorten the patient’s remaining time. Research on the topic is generally reassuring on the survival question: when properly administered, palliative sedation does not appear to hasten death. But emotional concerns do not dissolve with clinical reassurance. Having this conversation before a crisis arises, ideally while the patient can still participate, makes the decision far easier for everyone involved.
What Caregivers Are Rarely Told
Caring for someone with glioblastoma is qualitatively different from caring for someone with most other terminal illnesses. The neurological changes mean caregivers are often grieving the loss of the person they knew long before the person actually dies. This phenomenon, sometimes called “anticipatory grief,” is amplified in brain tumors because the disease attacks identity itself.
Despite this, caregiver preparedness remains poor. A study of end-of-life perceptions among caregivers of patients with high-grade gliomas found that only 41% felt confident they knew what to do at the time of death, and nearly half felt the healthcare team had not provided them with someone to turn to in distress. Caregivers reported high overall satisfaction with the medical care their loved one received, but communication and attention to the family’s needs were consistently identified as areas needing improvement.11PubMed Central. Caregiver perceptions of end-of-life care in patients with high-grade glioma
There are specific things caregivers can do to feel less blindsided:
- Ask directly: Request a meeting with the palliative care team specifically to discuss what the dying process will look like. Many care teams wait for families to ask rather than proactively walking them through it.
- Prepare for swallowing loss: Know which medications can be given by routes other than the mouth and have those prescriptions filled in advance.
- Understand seizures: Ask for training on how to administer non-oral rescue medications and what a seizure looks like in someone who is already semi-conscious.
- Accept changed communication: When the patient can no longer speak, touch, presence, and a calm voice still matter. There is no evidence that hearing is the last sense to fade, but there is also no evidence that an unresponsive patient cannot hear you.
Caregiver burnout in glioblastoma is not an afterthought; it is a predictable and well-documented consequence of the disease. Seeking respite care, counseling, and peer support groups is not a failure of love or commitment. The disease is relentless, and no one can sustain round-the-clock care indefinitely without help.
Why Advance Care Planning Needs to Happen Early
Glioblastoma erodes decision-making capacity faster than most cancers. The cognitive and personality changes described above mean that a patient who is fully capable of expressing their wishes at diagnosis may be unable to do so within months. This creates a narrow window for advance care planning, and it is a window that too many patients and families miss.
Data from South Korea illustrates the problem starkly: among glioblastoma patients who had life-sustaining treatment plans on file, roughly 84% of those forms were completed by family members rather than by the patients themselves.12PubMed Central. Current status of advance care planning, palliative care consultation, and end-of-life care in patients with glioblastoma in South Korea Family determination is not inherently wrong, but it raises questions about whether the documented wishes truly reflect what the patient would have chosen. And it places an enormous emotional burden on family members who must make life-and-death decisions while already grieving.
The conversations that matter most are the ones that happen early, while the patient is still cognitively intact. These include preferences about mechanical ventilation, resuscitation, feeding tubes, palliative sedation, and where the patient wants to die. They also include less medical but equally important questions: who should make decisions when the patient cannot, what matters most in their remaining time, and what level of intervention aligns with their values. A systematic review noted that standard functional assessment tools used across oncology perform poorly in glioblastoma because neurological events like seizures or sudden motor deficits can cause temporary drops in function that do not reflect the overall disease trajectory.13PubMed Central. Defining end-of-life in glioblastoma multiforme: a systematic review This unpredictability makes it even more important to have clear plans in place before a crisis forces rushed decisions.
Dying at Home Versus in a Hospital
Many glioblastoma patients and their families express a preference for death to occur at home. Whether this is achievable depends largely on the support infrastructure available. Home palliative care with access to subcutaneous medications, non-oral seizure rescue drugs, and regular nurse visits can make a comfortable death at home feasible for the majority of patients. The study that reported an 11% rate of palliative sedation was specifically conducted in a home care setting, demonstrating that even complex symptom management does not automatically require hospitalization.10PubMed. Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients
Hospital death, by contrast, tends to involve more aggressive interventions. Patients who arrive at the emergency department during a seizure or acute decline may end up in the ICU, where the mortality rate for glioblastoma patients on mechanical ventilation is around 60%, with sepsis and organ failure as the primary causes.2PubMed Central. Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis For patients whose goals are comfort-focused, an ICU admission in the final days is unlikely to align with their wishes and may prolong the dying process in ways that add suffering without meaningful benefit.
The gap between intention and reality is often bridged by preparation. Families who have had explicit conversations, who have a do-not-resuscitate order in place if appropriate, and who have home hospice enrollment arranged in advance are far more likely to achieve a death at home that matches the patient’s values. Those who have not had these conversations are more likely to call emergency services in a panic when symptoms escalate, which sets off a chain of interventions that can be difficult to reverse once started.